Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia.

Inclusion Criteria: * 1\. Aged 18 to 65 years (inclusive), male or female. * 2\. Patients diagnosed with schizophrenia according to ICD-10 criteria, with a Positive and Negative Syndrome Scale (PANSS) total score ≤ 70, judged as clinically stable for at least 28 days prior to screening (no medication changes or hospitalization due to condition changes). * 3\. Receiving treatment with ≤ 2 other oral antipsychotic medications, which must have been at a stable dose for ≥ 14 days before the first study injection (excluding prohibited medications). * 4\. Body weight ≥ 45 kg for females and ≥ 50 kg for males; Body Mass Index (BMI) between 18.5 and 35.0 kg/m² (inclusive). * 5\. Subject or partner has no pregnancy plan and agrees to use effective non-drug contraception during the study and for six months after the last dose. * 6\. Subjects and their legal guardians voluntarily sign the Informed Consent Form (ICF) and are able to comply with all study requirements. Exclusion Criteria: * 1.Diagnosis of any psychiatric disorder other than schizophrenia according to ICD-10 criteria. * 2.History or presence of clinically significant cardiovascular, hepatic, renal, gastrointestinal, psychiatric, or neurological diseases that, in the investigator's judgment, would affect participation in the study. * 3.Patients with Parkinson's disease, Lewy body dementia, or dementia-related psychosis. * 4.History or presence of Neuroleptic Malignant Syndrome (NMS). * 5.History or presence of epilepsy o…